Thomas Hill
CorpComms@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 12, 2024
Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is now available for prescription in Canada for the...
-
Jan 31, 2024
In partnership with Sumitomo Pharma Canada, Inc., Pfizer Canada ULC is proud to announce that supply of MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone acetate tablets 0.5 mg...
-
Dec 11, 2023
– DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia, with Positive Preliminary Data Presented at...
Nov 21, 2023–Time To Go™ Campaign Encourages People Experiencing Overactive Bladder (OAB) Symptoms to Talk to Their Healthcare Provider about Symptoms, Seek Diagnosis and Ask About GEMTESA® (Vibegron)–...
-
Nov 3, 2023
– ASH Preliminary Data Includes New Clinical Results in Relapsed or Refractory Myelofibrosis (TP-3654) and Relapsed or Refractory Acute Leukemia (DSP-5336) – CAMBRIDGE, Mass., Nov. 3, 2023...